Physician profile
Paul Seigel
NPI 1710921192
$4,336.81
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,453 · 2020: $359 · 2021: $841 · 2022: $764 · 2023: $461 · 2024: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $921.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $548.61 | 2019-2023 | Repatha |
| Medtronic Vascular, INC. | $514.38 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $385.72 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $341.25 | 2019-2024 | Xarelto |
| Pfizer INC. | $340.93 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $331.82 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $309.74 | 2019-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $266.77 | 2019-2024 | Eliquis |
| Boston Scientific Corporation | $259.54 | 2021-2024 | Watchman Flx |
| Medtronic, INC. | $174.06 | 2022 | |
| Esperion Therapeutics, INC. | $174.06 | 2021-2023 | Nexletol |
| Amarin Pharma, INC. | $163.59 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $110.63 | 2021-2024 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $66.18 | 2019 | |
| Abbott Laboratories | $60.94 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $57.59 | 2022-2023 | |
| Edwards Lifesciences Corporation | $38.94 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $36.90 | 2023 | Inpefa |
| United Therapeutics Corporation | $30.09 | 2023 | Tyvaso |
| Kestra Medical Technology Services, INC. | $27.93 | 2024 | Assure Wcd |
| Novo Nordisk INC | $23.39 | 2021 | |
| Baxter Healthcare | $21.20 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Kiniksa Pharmaceuticals International, Plc | $21.00 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.50 | 2023 | Jardiance |
| Allergan, INC. | $13.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Seigel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.